UroGen Pharma Ltd. 8-K

What Happened
UroGen Pharma Ltd. (URGN) announced its financial results for the quarter and full year ended December 31, 2025 and filed a Form 8-K on March 2, 2026 (Item 2.02). The company attached a press release with the results as Exhibit 99.1 to the filing; the submission also includes an Interactive XBRL cover page (Exhibit 104).

Key Details

• Filing date: March 2, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting periods: quarter and year ended December 31, 2025.
• Exhibit 99.1: Press release dated March 2, 2026 containing the reported results.
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL) embedded in the filing.

Why It Matters
This filing publicly communicates UroGen’s recent earnings and financial condition for investors and analysts; the attached press release will contain the specific revenue, profit/loss, cash position and other metrics investors use to assess near-term performance. Because the Form 8-K provides the official, timely disclosure (and XBRL data for machine readability), shareholders should review the press release and any subsequent filings (quarterly/annual reports) to see the detailed figures, compare to expectations, and determine potential impacts on valuation or near-term outlook.